CD274 and head and neck squamous cell carcinoma: Among R/M HNSCC patients with PD-L1 expression ≥1%, nivolumab as a first-line treatment was most likely to provide the best OS benefit (63.37%), while pem-chemo was most likely to offer the greatest PFS benefit (91.76%).